Cetuximab biobetter - Glycotope

Drug Profile

Cetuximab biobetter - Glycotope

Alternative Names: CetuGEX™; Cetuximab biosimilar - Glycotope; GT-MAB 5.2-GEX

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator GLYCOTOPE
  • Developer Glycotope
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I/II Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Renal cancer
  • Phase I Solid tumours

Most Recent Events

  • 20 May 2016 Cetuximab biobetter is still in phase II trials for Head and neck cancer (Late-stage disease, Metastatic disease, Recurrent) in Belgium, Germany, France, Italy, Poland, Romania and Spain
  • 20 May 2016 Phase-I/II development for Colorectal cancer, Non-small cell lung cancer, Gastric cancer and Renal cancer is ongoing in Germany
  • 31 Oct 2013 Glycotope completes a phase I trial in Solid tumours in Germany, Italy and Switzerland (NCT01222637)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top